Mobile Site ›
Print Friendly View

Test ID: OXYSX    
Oxycodone Screen, Chain of Custody, Urine

Useful For Suggests clinical disorders or settings where the test may be helpful

Detection of oxycodone and oxymorphone in urine following chain-of-custody procedures

 

Chain of custody is required whenever the results of testing could be used in a court of law. Its purpose is to protect the rights of the individual contributing the specimen by demonstrating that it was under the control of personnel involved with testing the specimen at all times; this control implies that the opportunity for specimen tampering would be limited.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Opiates are the natural or synthetic drugs that have a morphine-like pharmacological action. Medically, opiates are used primarily for relief of pain. Opiates include morphine and drugs structurally similar to morphine (eg, codeine, hydrocodone, hydromorphone, oxycodone, oxymorphone).

 

Oxycodone is metabolized to noroxycodone, oxymorphone, and their glucuronides and is excreted primarily via the kidney. The presence of oxycodone greater than 100 ng/mL indicates exposure to oxycodone within 2 to 3 days prior to specimen collection.

 

Oxymorphone is metabolized in the liver and excreted via the kidney primarily as the glucuronide conjugates. Oxymorphone is also a metabolite of oxycodone and therefore the presence of oxymorphone could also indicate exposure to oxycodone.

 

Chain of custody is a record of the disposition of a specimen to document who collected it, who handled it, and who performed the analysis. When a specimen is submitted in this manner, analysis will be performed in such a way that it will withstand regular court scrutiny

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Negative

Screening cutoff concentration:

 

Oxycodone: 100 ng/mL

Interpretation Provides information to assist in interpretation of the test results

A positive result indicates that the patient has used the drugs detected in the recent past. See individual tests (eg, OXYCU / Oxycodone with Metabolite Confirmation, Urine) for more information.

 

For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at http://www.mayomedicallaboratories.com/articles/drug-book/print-on-demand-select.php

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Other drugs in the opioid class, such as fentanyl, meperidine, methadone, and opiate antagonists such as naloxone, are not detected.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

1. Anderson DT, Fritz KL, Muto JJ: Oxycontin: the concept of a "ghost pill" and the postmortem tissue distribution of oxycodone in 36 cases. J Anal Toxicol 2002;26:448-459

2. Jannetto PJ, Gock SG: Oxycodone: Recognition and Pharmacogenomics. Clinical and Forensic Toxicology News, 2003 March

3. Cone EJ: Oxycodone Involvement in Drug Abuse Deaths: A DAWN-Based Classification Scheme applied to an Oxycodone Postmortem Database Containing over 1000 Cases. J Anal Toxicol 2003;27: 57-67

4. Baselt RC, Cravey RH: Oxycodone. In Disposition of Toxic Drugs and Chemicals in Man. Fourth edition. Chemical Toxicology Institute, Foster City, CA. 1995;572-574